Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience is attractive fundamentally because its biomarker-driven psychiatry strategy can enrich trials for patients most likely to respond, which should improve clinical success rates and strengthen eventual labeling across ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300. The biggest near-term driver is ALTO-207, where the PACE program now spans three trials, including a parallel Phase 3 adjunctive study and a planned monotherapy study, while independent PRIME-PRAXOL data validated pramipexole’s antidepressant signal and the ondansetron component addresses nausea. Financially, the July financing lifted pro forma cash to roughly $338 million, supporting planned operations through 2030 and giving the company time to advance multiple catalysts without near-term balance-sheet pressure.

Bears say

Alto Neuroscience is a clinical-stage biotech with promising but still unproven assets, and its dependence on biomarker-guided psychiatry leaves execution highly vulnerable to clinical readouts, regulatory outcomes, and safety signals. The pramipexole dataset from June supports the mechanism, but nausea in roughly 60% of treated participants highlights a meaningful tolerability issue that ALTO-207 is intended to address, underscoring that efficacy alone may not translate into a commercially viable profile. Financially, operating expenses rose to $29.1M from $18.7M, with R&D up 69% to $22.1M, and despite $244.2M in cash as of June 30, 2026 and about $338M pro forma after the July 2026 offering, the company is still expected to need additional funding and faces dilution risk if capital markets tighten.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of Oct 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.